The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•3 April 2026•

1 min read

Zacks Upgrades Applied Materials and Biotech Stocks to Buy Ratings

Key Facts

1Applied Materials (AMAT) has been upgraded to a 'Strong Buy' (Zacks Rank #1).

2Galectin Therapeutics (GALT) has been upgraded to a 'Buy' (Zacks Rank #2).

3Vivani Medical (VANI) has been upgraded to a 'Buy' (Zacks Rank #2).

Zacks Investment Research has upgraded Applied Materials (AMAT) to a "Strong Buy" (Zacks Rank #1), signaling robust growth potential for the semiconductor equipment giant. The upgrade cycle also extended to the biotechnology sector, with Galectin Therapeutics (GALT) and Vivani Medical (VANI) both raised to a "Buy" rating (Zacks Rank #2). These revisions are primarily driven by improving future earnings prospects and upward adjustments in analyst estimates. Zacks' ranking system focuses on earnings estimate revisions, which are often considered a reliable precursor to stock price appreciation. The positive outlook for Applied Materials reflects underlying strength in the tech sector, while the biotech upgrades highlight specific fundamental progress in clinical-stage firms. Investors typically view these quantitative rank changes as a signal of positive momentum in the underlying business performance.